Ovary - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Measures urinary oxalate.

₹666₹951

30% OFF

Ovary - Large Biopsy 3-6 cm: Comprehensive Medical Test Information Guide

Why is it done?
- Histopathological examination of ovarian tissue masses measuring 3-6 cm to determine the nature of the lesion (benign, malignant, or borderline)
- Primary indications include: ovarian cysts with suspicious imaging features, complex adnexal masses, elevated tumor markers with imaging findings, and masses with increasing size on follow-up imaging
- Performed when imaging findings are inconclusive and definitive diagnosis is required for treatment planning and prognosis
- Typically ordered in women of reproductive age or post-menopausal women presenting with persistent ovarian masses
- May be performed during surgical intervention or via image-guided minimally invasive procedures
- Helps differentiate between functional cysts, cystadenomas, cystadenocarcinomas, teratomas, and other ovarian neoplasms
Normal Range
- Normal results indicate benign pathology with no evidence of malignancy, atypia, or concerning features
- Benign findings include: simple cysts, corpus luteum, follicular cysts, serous cystadenomas, mucinous cystadenomas, mature teratomas, and fibromas
- Results are reported as categorical findings rather than numerical values
- Normal ranges are expressed as: Negative for malignancy or Benign findings
- Specimen adequacy is assessed (adequate vs. inadequate for diagnosis)
- No histologic atypia, increased mitotic activity, or necrosis in benign specimens
Interpretation
- Benign Findings: Non-neoplastic cysts, functional cysts, serous/mucinous cystadenomas, mature cystic teratomas, fibromas, or thecomas indicate no malignancy; conservative management may be considered
- Borderline/Low Malignant Potential (LMP): Presence of nuclear atypia without invasion; requires close clinical follow-up and may warrant additional treatment depending on stage and grade
- Malignant Findings: Evidence of invasive carcinoma (serous, mucinous, clear cell, endometrioid, or undifferentiated) requires immediate oncologic management, staging, and adjuvant therapy
- Tumor Grading: Grade 1 (well-differentiated), Grade 2 (moderately differentiated), or Grade 3 (poorly differentiated) correlates with prognosis and treatment intensity
- Factors Affecting Results: Specimen size and representation, fixation quality, patient age, menopausal status, and clinical presentation influence diagnostic accuracy
- Ancillary Studies: Immunohistochemistry, molecular testing, or electron microscopy may be performed to further characterize specific tumor types or confirm diagnosis
- Clinical significance: Results directly guide treatment decisions, prognosis estimation, and determination of need for chemotherapy or surgical staging
Associated Organs
- Primary Organ System: Female reproductive system, specifically the ovaries as part of the adnexal structures
- Diseases Commonly Associated: Epithelial ovarian cancer (serous, mucinous, clear cell, endometrioid), granulosa cell tumors, dysgerminomas, immature teratomas, and metastatic tumors from other organs
- Malignancy Complications: Peritoneal spread, ascites, bowel obstruction, hepatic metastasis, lymph node involvement, and distant metastasis to lungs, pleura, or other organs
- Biopsy-Related Complications: Infection, hemorrhage, organ perforation, peritonitis, or needle tract seeding (rare in large biopsies); infection risk increases with immunocompromised status
- Related Pelvic Structures: Fallopian tubes, uterus, peritoneum, and adjacent bowel may be involved in disease spread or complicated by biopsy procedure
- Associated Medical Conditions: PCOS (polycystic ovarian syndrome), endometriosis, inherited BRCA1/BRCA2 mutations, Lynch syndrome, and ovarian torsion
Follow-up Tests
- If Benign Findings: Routine follow-up ultrasound imaging in 6-12 months; no further intervention typically required unless symptomatic
- If Borderline/LMP Findings: Serial imaging (CT or MRI) every 3-6 months; CA-125 monitoring; gynecologic oncology consultation; possible staging laparotomy or laparoscopy
- If Malignant Findings: Urgent referral to gynecologic oncology; staging studies (CT chest/abdomen/pelvis, CA-125, HE4); definitive surgical staging; consideration for neoadjuvant chemotherapy; tumor markers monitoring
- Complementary Imaging Tests: Transvaginal ultrasound for further characterization; CT or MRI of abdomen and pelvis for staging; PET-CT for metabolic assessment of malignant lesions
- Tumor Marker Testing: CA-125, HE4, CEA, AFP, and beta-hCG depending on histologic type; baseline and follow-up measurements for treatment response assessment
- Genetic Testing: BRCA1/BRCA2 mutation testing recommended for malignant cases; assists with treatment selection and family counseling
- Surveillance Frequency: Benign: annual imaging; Borderline: every 3-6 months initially; Malignant: imaging every 3 months during treatment, then every 3-6 months based on clinical response
Fasting Required?
- Fasting: NO - Fasting is not required for this biopsy procedure
- Pre-Procedure Preparation: NPO (nothing by mouth) typically 4-6 hours if general anesthesia planned; clear fluids may be allowed until 2 hours before procedure
- Medication Adjustments: Discontinue anticoagulants (warfarin, DOACs) 3-5 days before procedure; antiplatelet agents (aspirin, clopidogrel) may need discontinuation based on bleeding risk; resume per clinical guidance post-procedure
- Other Preparation Requirements: Complete blood count and coagulation studies (PT/INR, PTT) prior to biopsy; pregnancy test if reproductive age (biopsy contraindicated if pregnant); remove all jewelry and metal objects; wear loose, comfortable clothing; arrange transportation as sedation may be used
- Bowel Preparation: If transvaginal approach: enema or bowel prep may be recommended; if transabdominal or laparoscopic: consider standard pre-operative bowel emptying
- Post-Procedure Instructions: Resume normal diet once alert; avoid strenuous activity for 24-48 hours; monitor for infection, excessive bleeding, or severe pain; report fever, chills, heavy vaginal bleeding, or persistent abdominal pain to physician

How our test process works!